辉瑞全球撤回镰状细胞病治疗药物Oxbryta 因导致并发症和死亡的风险增加

格隆汇
26 Sep 2024

格隆汇9月26日|据路透,美国制药商辉瑞周三表示,将从所有获批的市场撤回其镰状细胞病治疗药物Oxbryta,理由是该药物导致并发症和死亡的风险增加。辉瑞在2022年以54亿美元收购Global Blood Therapeutics时获得了Oxbryta。该公司报告称,2023年该疗法的收入为3.28亿美元。此次撤药发生在欧洲卫生监管机构人用药品委员会周四召开“特别会议”审查辉瑞药物之前。在一项对...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10